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pancreatic 	 neuroendocr ine	 tumour	 (GEP-NET), 	 descr ibed	 as 	 the	 age-





















































































































































































































Evaluation of therapy outcome
The	treatment	of	GEP-NETs	is	extremely	variable	and	different	treatment	modalities	
are	currently	used	and	developed.	To	have	 insight	 in	and	for	comparison	with	






































































































































































































WHO, World Health Organization; SWOG, Southwest Oncology Group; RECIST, Response Evaluation 
Criteria in Solid Tumours; CR, complete response; PR, partial response; SD, stable disease; PD, progressive 
disease
(a) Cancer 1981; 47:207-214
(b) J Natl Cancer Inst 2000; 92:205-216
(c) target lesions, all measurable lesions up to a maximum of five lesions per organ and 10 lesions in total, 
representative of all involved organs










































Survival Term Definition† Endpoint

















































































































































































































Most	 reports	on	OLT	are	single	centre	studies	 that	describe	a	 limited	number	
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Abbreviations: IFN-α, interferon-α; RFA, radiofrequency ablation; LIT T, laser-induced Interstitial 



































in	brain,	gastrointestinal	tract,	and	kidney.	Proc Natl Acad Sci U S A.	1992;	89:251-
255.
4.	 Yamada	Y,	Kagimoto	S,	Kubota	A,	 et	 al.	Cloning,	 functional	 expression	 and	
pharmacological	characterization	of	a	fourth	(hSSTR4)	and	a	fifth	(hSSTR5)	human	












European Journal of Epidemiology.	1997;	13:357-359.
11.	 Berge	T,	Linell	F.	Carcinoid	tumours.	Frequency	in	a	defined	population	during	a	










Classification	of	Tumours.	Geneva: World Health Organization.	1980.
17.	 Kloppel	G,	Perren	A,	Heitz	PU.	The	Gastroenteropancreatic	Neuroendocrine	Cell	





















25.	 Goede	AC,	Caplin	ME,	Winslet	MC.	Carcinoid	tumour	of	the	appendix.	Br J Surg.	
2003;	90:1317-1322.
26.	 Stinner	B,	Rothmund	M.	Neuroendocrine	tumours	(carcinoids)	of	the	appendix.	Best 
Pract Res Clin Gastroenterol.	2005;	19:729-738.











does	intervention	alter	outcomes?	J Am Coll Surg.	2000;	190:432-445.
33.	 Boudreaux	JP,	Putty	B,	Frey	DJ,	et	al.	Surgical	treatment	of	advanced-stage	carcinoid	
tumors:	lessons	learned.	Ann Surg.	2005;	241:839-45;	discussion	845-846.





36.	 Bechstein	WO,	Neuhaus	 P.	 Liver	 transplantation	 for	 hepatic	metastases	 of	



























































50.	 Ruszniewski	P,	O’Toole	D.	Ablative	 therapies	 for	 liver	metastases	of	 gastro-
enteropancreatic	endocrine	tumors.	Neuroendocrinology.	2004;	80	Suppl	1:74-78.
51.	 Toumpanakis	C,	Meyer	T,	Caplin	ME.	Cytotoxic	treatment	including	embolization/	
chemoembolization	for	neuroendocrine	tumours.	Best Pract Res Clin Endocrinol 
Metab.	2007;	21:131-144.
52.	 O’Toole	D,	Ruszniewski	P.	Chemoembolization	and	other	ablative	therapies	for	liver	
metastases	of	gastrointestinal	endocrine	tumours.	Best Practice & Research Clinical 
Gastroenterology.	2005;	19:585-594.
53.	 Ajani	JA,	Carrasco	CH,	Wallace	S.	Neuroendocrine	tumors	metastatic	to	the	liver.	














59.	 Grady	ED.	 Intrahepatic	 aterial	90-yttrium	resin	 spheres	 to	 treat	 liver	 cancer.	
International Journal of Nuclear Medicine and Biology.	1978;	5:253-254.
60.	 Simon	N,	Silverstone	SM,	Roach	LC,	Warner	RR,	Baron	MG,	Rudavsky	AZ.	Intra-


















for	unresectable	hepatic	tumors.	The American Journal of Surgery.	2001;	182:552-
557.




and	radiofrequency	ablation.	World J Surg Oncol.	2005;	3:75-83.
69.	 Veenendaal	LM,	Borel	Rinkes	IH,	Lips	CJ,	van	Hillegersberg	R.	Liver	metastases	of	
neuroendocrine	tumours;	early	reduction	of	tumour	load	to	improve	life	expectancy.	
World J Surg Oncol.	2006;	4:35-41.
70.	 Veenendaal	LM,	Borel	Rinkes	IH,	van	Hillegersberg	R.	Multipolar	radiofrequency	
ablation	of	 large	hepatic	metastases	of	endocrine	tumours.	Eur J Gastroenterol 
Hepatol.	2006;	18:89-92.
71.	 de	Baere	T,	Elias	D,	Dromain	C,	et	 al.	Radiofrequency	ablation	of	 100	hepatic	























somatostatin	analogue.	Eur J Nucl Med.	1993;	20:431-433.
80.	 Dorr	U,	Wurm	K,	Horing	E,	Guzman	G,	Rath	U,	Bihl	H.	Diagnostic	reliability	of	
somatostatin	receptor	scintigraphy	during	continuous	treatment	with	different	




























































92.	 Moertel	CG,	 Lefkopoulo	M,	 Lipsitz	 S,	Hahn	RG,	Klaassen	D.	 Streptozocin-
doxorubicin,	streptozocin-fluorouracil	or	chlorozotocin	in	the	treatment	of	advanced	
islet-cell	carcinoma.	N Engl J Med.	1992;	326:519-523.
93.	 Moertel	CG,	Hanley	JA,	Johnson	LA.	Streptozocin	alone	compared	with	streptozocin	











patients	with	metastatic	islet-cell	carcinoma.	Am J Clin Oncol.	1998;	21:36-38.
98.	 Delaunoit	T,	Ducreux	M,	Boige	V,	et	al.	The	doxorubicin-streptozotocin	combination	
for	the	treatment	of	advanced	well-differentiated	pancreatic	endocrine	carcinoma:	a	
judicious	option?	European Journal of Cancer.	2004;	40:515-520.




in	advanced	APUD	tumors.	Am J Clin Oncol.	1988;	11:490-495.


















































































and	clinical	studies.	Am J Physiol Imaging.	1986;	1:96-103.
122.	 Hoefnagel	CA,	den	Hartog	Jager	FC,	Taal	BG,	Abeling	NG,	Engelsman	EE.	The	role	
of	I-131-MIBG	in	the	diagnosis	and	therapy	of	carcinoids.	Eur J Nucl Med.	1987;	
13:187-191.
123.	 Shapiro	B.	Ten	years	of	experience	with	MIBG	applications	and	the	potential	of	new	
radiolabeled	peptides:	a	personal	overview	and	concluding	remarks.	Q J Nucl Med.	
1995;	39:150-155.















management	of	neural	crest	tumours.	Eur J Nucl Med.	1994;	21:561-581.
130.	 Bomanji	JB,	Wong	W,	Gaze	MN,	et	al.	Treatment	of	neuroendocrine	tumours	in	
adults	with	131I-MIBG	therapy.	Clin Oncol (R Coll Radiol).	2003;	15:193-198.
131.	 Buscombe	JR,	Caplin	ME,	Tibbals	J,	Watkinson	AJ,	Hilson	AJW.	Optimizing	therapy	





133.	 Pathirana	AA,	Vinjamuri	S,	Byrne	C,	Ghaneh	P,	Vora	 J,	 Poston	GJ.	 131I-MIBG	
radionuclide	therapy	is	safe	and	cost-effective	in	the	control	of	symptoms	of	the	











by	 ni fedipine	 of 	 13 1I -meta-iodobenzylguanidine	 kinetics 	 in 	 malignant	









the	BCR-ABL	Tyrosine	Kinase	in	Chronic	Myeloid	Leukemia.	N Engl J Med.	2001;	
344:1031-1037.
141.	 Demetri	GD,	von	Mehren	M,	Blanke	CD,	et	al.	Efficacy	and	Safety	of	 Imatinib	




143.	 Duran	 I,	 Salazar	R,	Casanovas	O,	 et	 al.	New	drug	development	 in	digestive	
neuroendocrine	tumors.	Ann Oncol.	2007;	18:1307-1313.
144.	 Yao	JC.	Molecular	targeted	therapy	for	carcinoid	and	islet-cell	carcinoma.	Best Practice 
& Research Clinical Endocrinology & Metabolism.	2007;	21:163-172.
145.	 Yao	JC,	Ng	C,	Hoff	PM,	et	al.	Improved	progression	free	survival	(PFS),	and	rapid,	
sustained	decrease	in	tumor	perfusion	among	patients	with	advanced	carcinoid	





of Clinical Oncology (Meeting Abstracts).	2005;	23:310s.
148.	 Hobday	TJ,	Holen	K,	Donehower	R,	et	al.	A	phase	II	trial	of	gefitinib	in	patients	(pts)	
with	progressive	metastatic	neuroendocrine	tumors	(NET):	A	Phase	II	Consortium	
(P2C)	study.	J Clin Oncol (Meeting Abstracts).	2006;	24:4043.






































Peptide receptor radionuclide 
therapy
 
Jaap J.M. Teunissen, Dik J. Kwekkeboom, Marion de Jong, Jan-Paul Esser, Roel�� Valkema 
and Eric P. Krenning


























RADIONUCLIDES AND SOMATOSTATIN ANALOGUES IN 
















































* Number of cells based on an average tumour cell size of 20 μm; ~, approximately
Besides	γ-radiation,	which	makes	111In	a	suitable	radionuclide	for	imaging,	it	emits	
both	Auger	and	conversion	electrons	with	a	medium-to-short	tissue	penetration	
range	 (0.02–10	 and	 200–500	µm,	 respectively).	 In	 vitro	 PRRT	 studies	with	

















































Jong	et al.	 20	 reported	the	results	of	such	a	combination	versus	single	analogue	













































































Table 2. Affinity	profiles	 (IC50)	a	 for	human	SSTR1-SSTR5	(hSSTR1-5)	of	a	 series	of	
somatostatin	analogues
Peptides hSSTR1 hSSTR2 hSSTR3 hSSTR4 hSSTR5
SS-28 5.2	±	0.3	(19) 2.7	±	0.3	(19) 7.7	±	0.9	(19) 5.6	±	0.4	(19) 4.0	±	0.3	(19)
Octreotide >10,000	(5) 2.0	±	0.7	(5) 187	±	55	(3) >1,000	(5) 22	±	6	(5)
DTPA-
octreotide
>10,000	(6) 12	±	2	(5) 376	±	84	(5) >1,000	(5) 299	±	50	(6)
111In-octreotide >10,000	(5) 22	±	3.6	(5) 182	±	13	(5) >1,000	(5) 237	±	52	(5)
DOTATOC >10,000	(7) 14	±	2.6	(6) 880	±	324	(4) >1,000	(6) 393	±	84	(6)
90Y-
DOTATOC
>10,000	(4) 11	±	1.7	(6) 389	±	135	(5) >10,000	(5) 114	±	29	(5)
DOTALAN >10,000	(7) 26	±	3.4	(6) 771	±	229	(6) >10,000	(4) 73	±	12	(6)
90Y-DOTALAN >10,000	(3) 23	±	5	(4) 290	±	105	(4) >10,000	(4) 16	±	3.4	(4)
DOTA-OC >10,000	(3) 14	±	3	(4) 27	±	9	(4) >1,000	(4) 103	±	39	(3)
90Y-DOTA-OC >10,000	(5) 20	±	2	(5) 27	±	8	(4) >10,000	(4) 57	±	22	(4)
DTPA-Tyr3-
octreotate
>10,000	(4) 3.9	±	1	(4) >10,000	(4) >1,000	(4) >1,000	(4)
111In-DTPA-
Tyr3-octreotate
>10,000	(3) 1.3	±	0.2	(3) >10,000	(3) 433	±	16	(3) >1,000	(3)
DOTA-Tyr3-
octreotate
>10,000	(3) 1.5	±	0.4	(3) >1,000	(3) 453	±	176	(3) 547	±	160	(3)
90Y-DOTA-
Tyr3-octreotate
>10,000	(3) 1.6	±	0.4	(3) >1,000	(3) 523	±	239	(3) 187	±	50	(3)
Modified from Reubi et al. 26 




The	 first	 radiolabelled	 somatostatin	 analogue	 therapy	 in	GEP	patients	with	
advanced-stage	disease	was	 based	on	 the	 administration	of	high	dosages	 of	
111In-octreotide,	which	 at	 that	 time	was	 available	 for	 diagnostic	 purposes	
(Table	3)	6,7,30,31.
The	total	cumulative	dose	varied	from	3.1	GBq	up	to	160.0	GBq.	In	a	report	by	















Authors [Ref.] No. of 
patients
PD before therapy Cum dose 
(GBq) 




































Cum dose, cumulatieve dose of 111In-octreotide; N/I, not indicated
a Criteria of Tumour Response: PR (partial remission), > 50%reduction of tumour size; SD (stable disease), 
< 25% reduction or increase of tumour size; PD (progressive disease), > 25% increase of tumour size. 



























































































































CR PR MR ‡ SD PD CR + PR
[90Y-DOTA0, Tyr3]octreotide























































































































* Criteria of Tumour Response (SWOG); CR (complete remission), no evidence of disease; PR (partial 
remission), > 50% reduction of tumour size; SD (stable disease), < 25% reduction or increase of tumour 
size; PD (progressive disease), > 25% increase of tumour size; ‡, modification of SWOG criteria including 

























































































Valkema	et al.	[6]		 [111In-DTPA0]octreotide 50 10% 15% 2% 3	AML/MDS




Bodei	et al.	[39] [90Y-DOTA0,Tyr3]octreotide 40 7% 3% 7%
Otte	et al.	[48] [90Y-DOTA0,Tyr3]octreotide 29 3% 7% 0% 4	Renal	*
Waldherr	et al.	[16] [90Y-DOTA0,Tyr3]octreotide 39 0 3% 0% 1	Renal	










Percentages are based on patient numbers. AML: acute myeloid leukaemia; MDS: myelodysplastic 
syndrome 
§, Most of the mentioned haematologic toxicities were transient. See reference for more detailed 
information;
*, No amino-acid infusion in half of the patients; 


























































































































































































































































































































**P<0.01;	NS,	not	 significant	 (two-sided	analysis	of	variance;	P<0.05	was	 considered	
significant).	(Modified	from	Teunissen	et al.66).
The	concomitant	expression	of	these	receptors	could	be	used	in	the	future	in	a	
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	 	 i.	 Toxicity
	 	 ii.	 Effects	on	tumour	size
	 	 iii.	 Side-effects
	 	 iv.	 Quality	of	life
-	to	investigate	the	feasibility	of	peptide	receptor	radionuclide	therapy	in	patients	
with	non-radioiodine	avid	differentiated	thyroid	carcinoma.










tumours	treated	with	[177Lu-	DOTA0,Tyr3]octreotate,	whereas chapter 4 describes	
long-term	changes	in	hormonal	status	after	therapy.	The	differential	uptake	of	[177Lu-
DOTA0,Tyr3]octreotate	versus	[177Lu-	DOTA0,Tyr3]octreotide	is	evaluated	in	chapter 
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Figure 1A–C. Planar	scans	of	 the	abdomen,	3	days	after	 the	 injection	of	200	mCi	 177Lu-
octreotate	in	a	patient	with	liver	metastases	of	an	operated	neuroendocrine	pancreatic	tumour.	



















Table 1. Tumour	responses	in	34	patients,	3	months	after	the	final	administration	of	 177Lu-
octreotate.	Three	patients	with	PD	died	before	reaching	their	final	dose.
RESPONSE Total
Tumour	type CR PR SD PD
Carcinoid 4	(33%) 6	(50%) 2	(17%) 12
NE	Pancreas 1	(8%) 1	(8%) 7	(58%) 3	(25%) 12
NE	unknown	origin 4	(57%) 1	(14%) 2	(29%) 7
Gastrinoma 3	(100%) 3
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profiles	for	human	somatostatin	receptor	subtypes	SST1-SST5	of	somatostatin	





































































































Radiolabeled somatostatin analog 
[177Lu-DOTA0,Tyr3]octreotate in 
patients with endocrine 
gastroenteropancreatic tumors
Dik J. Kwekkeboom, Jaap J. Teunissen, Willem H. Bakker, Peter P. Kooij, Wouter W. 
de Herder, Richard A. Feelders, Casper H. van Eijck, Jan-Paul Esser, Boen L. Kam 
and Eric P. Krenning 
Journal of Clinical Oncology 2005; 23:2754-2762 
Abstract
Purpose

















































































































































































































































































































































































































Table 1. Tumor	 responses	 in	 125	 patients	 3	months	 after	 the	 last	 administration	 of	
177Lu-octreotate




















Carcinoid - - 13 20 13 20 28 42 12 18 66
NE	pancreas 3 9 7 22 7 22 11 34 4 13 32
NE	unknown	
origin
- - 6 35 2 12 4 24 5 29 17
Gastrinoma - - 5 63 2 25 1 12 - - 8
Insulinoma - - 1 50 - - - - 1 50 2
Total 3 2 32 26 24 19 44 35 22 18 125
NOTE. Ten patients with PD died before reaching their final dose.
Abbreviations: CR, complete remission; PR, partial remission; MR, minor response; SD, stable disease; PD, 














Factor No. Patients No. % P (χ2) P (logistic) No. % P (χ2) P (logistic)
[111In-DTPA0]octreotide scintigraphy uptake
				≈	Liver 4 1 25 .008 .002 0 0 NS NS
				>	Liver 97 40 41 21 22
				>>	Liver 24 18 75 1 4
Tumor type
				Gastrinoma 8 7 88 .018 NS 0 0 NS NS
				Other 117 52 44 22 19
Tumor mass
				Limited 21 14 67 NS NS 0 0 .045 .028
				Moderate 78 35 45 15 19
				Extensive 26 10 38 7 27
Liver metastases
				None/moderate 91 48 53 .042 .017 11 12 .008 NS
				Extensive 34 11 32 11 32
Bone metastases
				Absent 94 48 51 NS NS 15 16 NS NS
				Present 31 11 36 7 23
Weight loss
				Absent 103 50 49 NS NS 12 12 .000 NS
				Present 22 9 41 10 46
KPS
				>	70 104 53 51 NS NS 10 10 .000 .000
				≤	70 21 6 29 12 57
Progressive at baseline
				No 34 16 47 NS NS 4 12 NS NS
				Yes 53 26 49 13 25
NOTE: Remission includes CR, PR, and MR. All tumor characteristics listed in the first column pertain to 
baseline observations. Tumor mass was judged on [111In-DTPA0]octreotide scintigrams, and liver involvement 
was judged on CT/MRI. Weight loss was scored positive if it at least amounted to 1 kg per month, existing 
for at least 3 months. 
Abbreviations: PD, progressive disease; ≈, Liver, approximately equal to liver uptake; > Liver, more than liver 
uptake; >> Liver, very high uptake; KPS, Karnofsky performance score; NS, not significant; CR, complete 
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At baseline Follow-up (6 weeks)
Mean SD Mean SD Change P*
Global quality of life †
Global	health-status/quality	of	life 69.0 20.8 78.2 16.9 9.2 <	0.01
Functional scales †
Physical 80.8 19.3 84.6 20.4 3.8 0.07
Role 67.0 31.7 82.0 25.2 15.0 <	0.01
Emotional 77.7 15.7 85.8 15.5 8.1 <	0.001
Cognitive 88.7 16.0 88.3 17.3 -0.4 0.89
Social 80.7 22.7 90.3 21.3 9.6 <	0.01
Symptom scales ‡
Fatigue 31.9 24.4 22.8 22.5 -9.1 <	0.01
Nausea/Vomiting 6.7 16.5 5.0 11.3 -1.7 0.46
Pain 23.3 28.8 15.0 20.0 -8.3 <	0.05
Single items ‡
Dyspnea 16.3 23.7 17.3 27.1 1.0 0.71
Insomnia 26.0 30.3 14.3 21.5 -11.7 <	0.01
Appetite	loss 10.2 19.5 8.7 21.1 -1.5 0.70
Constipation 8.8 20.2 6.1 16.2 -2.7 0.32
Diarrhea 16.7 26.3 12.2 18.9 -4.5 0.26
Economical	impact 5.3 14.1 5.3 15.6 0.0 1.00
Body Weight 71.3 14.5 74.0 15.5 2.7 0.01
Karnofsky Performance Status 
Scale
87.2 12.3 87.9 12.0 0.7 0.52
NOTE Mean scores and ± SD of the EORTC QLQ-C30 questionnaire before and after (6 weeks follow-up 
visit) 177Lutetium-octreotate therapy. Body weight and KPS are also shown.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality 
of Life Questionnaire C30; SD, standard deviation.
*: P < .05 was regarded as statistical significant.
†: Scores ranges from 0 to 100, with a higher score representing a higher level of function. 
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Treatment	with	 radiolabelled	 somatostatin	 analogues,	 or	 peptide	 receptor	













































































































































































































































































































































































































n	>	6.5 0	(0%) 5	(100%) 5
n	≤	6.5 57	(90%) 6*	(10%) 63
Total 57 11 68
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combination	of	 a	 large	percentage	of	HCTC	patients	with	positive	 lesions	on	
111In-octreotide	scintigraphy,	relatively	high	tumor	uptake	of	 177Lu-DOTATATE	
compared	with	PTC	or	FTC,	and	the	favorable	outcomes	observed	in	our	patients	
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(<10	ng	ml-1,	n=11)	 and	 those	 from	 the	 group	with	high	 serum	Tg-on	 levels	
(>10	ng	ml-1,	n=39).	In	the	latter	group,	85%	of	patients	had	a	positive	SRS	whereas	
in	the	group	with	low	serum	Tg-on	levels	only	27%	of	patients	had	a	positive	SRS.	






































































1995 3 2	PTC;	1	insular	TC 120-60	000	(3) 2	out	of	3	(67%) [10]
1996 16 11	FTC;	5	PDTC 2-42	500	(16) 12	out	of	15	(75%) [11]
1996 6 5	FTC;	1	PTC 	NA NA 6	out	of	6	(100%) [12]
1998 16 15	PTC;	1	vesicular	TC	 <	0.2-1440	(11) 3	out	of	16	(19%) [16]





2001 25 9	FTC;	16	PTC <	1.5-14	910	(25) 6	out	of	8	(75%) [13]
2003 17 1	FTC;	4	PTC;	12	HCTC NA NA 14	out	of	17	(82%) [14]




0.7-5250	(40) 171-5850	(3) 22	out	of	43	(51%) [18]
a Abbreviations: FTC, follicular thyroid carcinoma; HCTC, Hürthle cell thyroid carcinoma; NA, not available; 
PTC, papillary thyroid carcinoma; SRS, somatostatin receptor scintigraphy; TC, thyroid carcinoma; Tg, 
thyroglobulin
b Tg-off, thyroglobulin levels without TSH suppressive treatment (L-thyroxine); Tg-on, thyroglobulin levels 
under TSH suppressive treatment

























In	 summary,	 these	 studies	 indicate	 that	 anatomical	 localization	 and	 tumor	
size/extent	of	disease	are	important	in	determining	the	outcome	of	SRS	in	patients	
with	non-radioiodine-avid	DTC.	











































































































1995 110 	WBS 	NA	 4h,	24h	and	48h N [10]
1996 120-200 	WBS;	SPECT 	10	cm/min 4h,	24h	and	48h N [11]
1996 220 	Planar	spot	images 	15	min 24h	and	48h Y [12]
1998 137-200 	Planar	spot	images 	5	min	and	10	min	 1h,	4h	and	24h Y [16]
1999 111 	WBS;	SPECT 	8	cm/min 24h	and	48h N [17]
2001 110-170 	WBS;	SPECT 	10	cm/min 4h	and	24h N [19]
2001 222 	Planar	spot	images;	SPECT 	15	min 24h	and	48h Y [13]
2003 111 	WBS;	SPECT 	NA 24h	and	48h N [14]








a Abbreviations: MBq, megabecquerel; NA, not available; SPEC T, single-photon emission computed 
tomography; WBS, whole-body scan;
 b Y = 111In-octreotide scintigraphy following the procedure guidelines for somatostatin receptor scintigraphy 
as described before [26]; N = different protocol 
c the 48h post injection scan was only performed when high background uptake was present on the 24h post 
injection scan to increase the sensitivity
NOVEL RADIOLABELED SOMATOSTATIN ANALOGS IN 
DTC 
Alternative	 radiolabeled	 somatostatin	 analogs	 are	 under	 investigation	 for	
SRS	27,	28.	Gabriel	et	al.29	studied	the	use	of	a	new	radiolabeled	somatostatin	analog	
99mTc-EDDA/HYNIC-TOC	 [99mTc-	 labeled	hydrazinonicotinyl	 (HYNIC)-Tyr3-
octreotide	(TOC)	coupled	with	ethylene	diamine	diacetic	acid	(EDDA)	as	a	co-





























































Recently,	Rodrigues	 et al.	 31	 reported	 results	 of	 in	 vitro	binding	 studies	 and	
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The	 aim	of	 this	 thesis	was	 to	 evaluate	 the	 efficacy	of	 treatment	with	 [177Lu-
DOTA0,Tyr3]octreotate	(177Lu-DOTATATE)	therapy	in	patients	with	somatostatin	
receptor	positive	GEP-NETs	in	terms	of	toxicity,	effects	on	tumour	size	and	number,	










































































































Another	 interesting	observation	 is	 the	decrease	of	both	LH	and	FSH	 levels	 in	
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Krenning,	was	het	gebruik	van	 radioactief	 gelabelde	 somatostatine-analogen	



































































































































































In	hoofdstuk 4 	wordt	 ingegaan	 op	 de	 korte-	 en	 langetermijneffecten	 van	
177Lu-DOTATAAT	therapie	op	de	hormonale	functies.	Aangezien	PRRT	een	systemisch	
toegediende	therapie	is	en	omdat	vele	endocriene	organen	somatostatinereceptoren	














































































































































































































De	 conclusie	 die	 getrokken	 kan	worden	 uit	 dit	 literatuuroverzicht	 is	 dat	
somatostatinereceptor	scintigrafie	behulpzaam	kan	zijn	om	de	tumoren	te	localiseren	
indien	er	aanwijzingen	zijn	voor	aanwezigheid	van	ziekte	door	bijvoorbeeld	een	
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